Evotec Faces a Delayed Turnaround as Guidance Cuts and Analyst Downgrades Mount
Published on 07/17/2026 at 05:52 | Redaktion boerse-global.de
Evotecâs latest setback is less about a single bad day on the market than a broader question of timing. The company has pushed back its recovery plans, cut its full-year outlook and left analysts racing to catch up with a much weaker earnings picture than they had modeled only days earlier.
The biotech group now expects 2026 revenue of EUR 570 million to EUR 610 million, down from the previously targeted EUR 700 million to EUR 780 million. Its adjusted EBITDA view has swung even more sharply: instead of EUR 0 million to EUR 40 million, Evotec now sees a loss of between EUR 70 million and EUR 105 million.
Those numbers followed the preliminary half-year report released on 13 July 2026. For the first six months, the company said group revenue came in at about EUR 300.1 million and adjusted EBITDA at around EUR minus 42.7 million. Management says the weaker guidance is mainly a matter of timing, not a structural break in the business.
A large part of the shortfall comes from partnership income that arrived later than expected. Evotec said roughly 40% of the gap was tied to existing collaborations where milestone payments were pushed back, while another 45% stemmed from delays in newly renegotiated agreements. The remaining 15% reflected lower revenue recognition.
Should investors sell immediately? Or is it worth buying Evotec?
The companyâs own message to investors is that extended sales cycles at key partners slowed the process, rather than any fundamental loss of demand. That distinction matters because Evotec has spent the past year reshaping itself for a more profitable phase of growth by 2028. In April 2025, it set out a strategic reset built around core capabilities and a simpler operating model. The associated âPriority Resetâ programme is expected to generate EUR 40 million in annual savings, but the timetable is slipping.
That delay has left the market with little patience. On Thursday, Evotec shares traded at EUR 3.48, only about 9% above the 52-week low of EUR 3.19 set on Monday this week. The stock has lost 53.12% over the past 12 months, while the RSI stands at 21.0 and 21.2 in the latest readings, both signalling a deeply oversold position. Volatility, at 64.16%, underscores how unsettled trading remains.
Analysts have been forced to recalibrate just as quickly. Deutsche Bank Research cut its price target to EUR 3.50 from EUR 4.50 while keeping a âHoldâ rating. The move came two days after the bank had initially left its EUR 4.50 target unchanged in the wake of the warning, a turnaround that analyst Fynn Scherzler said reflected how unexpectedly severe the revision had been.
Other firms have responded in different ways. TD Cowen moved from âBuyâ to âHoldâ and reduced its target to EUR 4 from EUR 7. H.C. Wainwright lowered its target to EUR 4.00 from EUR 7.00 but kept a âBuyâ recommendation. Berenberg cut its view to âHoldâ from a previous target of EUR 9.40, trimming the price target to EUR 3.60. RBC has so far held onto its âOutperformâ call and EUR 10 target.
Evotec at a turning point? This analysis reveals what investors need to know now.
The range of reactions shows how quickly the old assumptions have become outdated. Much of the current analyst consensus was compiled before the latest guidance cut, with only TD Cowen adjusting immediately after the warning and several other estimates still dating from March to May 2026. More revisions are likely to follow as models are updated.
Evotec is scheduled to publish its full half-year results on 13 August 2026. Until then, investors will be watching one question above all: whether the promised partner milestones arrive soon enough to steady the numbers, or whether the companyâs turnaround remains pushed further into the future.
Ad
Evotec Stock: New Analysis - 17 July
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
